Last 12 months
Inside the activity.
2 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2025 Filed Jan 13, 2025 17:03 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Erani Dennis10% owner
Wisdom Starr10% owner
RED Holdings, LLC10% owner
|
GiftClass A Common Stock | 6,401,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000728 · form4.xml · nonDerivative · entry 3 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,402 F1 · kind: On January 9, 2025, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 17:03 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Erani Dennis10% owner
Wisdom Starr10% owner
RED Holdings, LLC10% owner
|
GiftClass A Common Stock | 6,401,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000728 · form4.xml · nonDerivative · entry 2 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 51,085,402 F1 · kind: On January 9, 2025, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 17:03 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Erani Dennis10% owner
Wisdom Starr10% owner
RED Holdings, LLC10% owner
|
GiftClass A Common Stock | 6,401,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000728 · form4.xml · nonDerivative · entry 1 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,402 F1 · kind: On January 9, 2025, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 19:20 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
ERANI ALBERT10% owner
|
GiftClass A Common Stock | 1,710,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000286 · form4.xml · nonDerivative · entry 3 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner ERANI ALBERT · CIK 0001074084 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,403 F1 · kind: On December 31, 2024, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 19:20 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
ERANI ALBERT10% owner
|
GiftClass A Common Stock | 1,710,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000286 · form4.xml · nonDerivative · entry 2 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner ERANI ALBERT · CIK 0001074084 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 51,085,403 F1 · kind: On December 31, 2024, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 19:20 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
ERANI ALBERT10% owner
|
GiftClass A Common Stock | 1,710,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000286 · form4.xml · nonDerivative · entry 1 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner ERANI ALBERT · CIK 0001074084 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,403 F1 · kind: On December 31, 2024, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 19:22 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Erani Dennis10% owner
Wisdom Starr10% owner
RED Holdings, LLC10% owner
|
GiftClass A Common Stock | 1,710,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000287 · form4.xml · nonDerivative · entry 3 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,403 F1 · kind: On December 31, 2024, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 19:22 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Erani Dennis10% owner
Wisdom Starr10% owner
RED Holdings, LLC10% owner
|
GiftClass A Common Stock | 1,710,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000287 · form4.xml · nonDerivative · entry 2 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 51,085,403 F1 · kind: On December 31, 2024, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 19:22 UTC |
Ades Alan A.Director · 10% owner
Ades Josette10% owner
Erani Dennis10% owner
Wisdom Starr10% owner
RED Holdings, LLC10% owner
|
GiftClass A Common Stock | 1,710,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-000287 · form4.xml · nonDerivative · entry 1 Ades Alan A. · CIK 0001757286 · Director · 10% owner Ades Josette · CIK 0002050939 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,403 F1 · kind: On December 31, 2024, the reported securities, which were directly held by Alan A. Ades, a member of the Group (as defined below), were transferred to his spouse, Josette Ades, who is a member of the Group, as a gift for no consideration for estate planning purposes. Alan A. Ades disclaims beneficial ownership of the securities held by his spouse, and this report shall not be deemed an admission that Alan A. Ades is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. None of the other members of the Group has a pecuniary interest in the transferred securities. F2 · balance_after: Reflects the total number of securities held by the Group. There was no change to the total number of securities because, at all times, the transferred shares were held, either directly or indirectly, by a member of the Group. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 01:03 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 5,585 | $3.49 | $19,491.65 |
DisclosureSEC source: 0001062993-24-020701 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,039,194 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.36 to $3.5275, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 01:03 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 55,615 | $3.36 | $186,866.40 |
DisclosureSEC source: 0001062993-24-020701 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,044,779 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.2806 to $3.50, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 01:08 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 43,359 | $3.55 | $153,924.45 |
DisclosureSEC source: 0001062993-24-020566 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,100,394 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.495 to $3.65, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 01:08 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 157,448 | $3.64 | $573,110.72 |
DisclosureSEC source: 0001062993-24-020566 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,143,753 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.72, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| December 10, 2024 Filed Dec 13, 2024 01:08 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 58,525 | $3.64 | $213,031.00 |
DisclosureSEC source: 0001062993-24-020566 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,301,201 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.4531 to $3.74, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:05 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 41,052 | $3.52 | $144,503.04 |
DisclosureSEC source: 0001062993-24-020285 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,359,726 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported above. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.48 to $3.69, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 01:05 UTC |
Gillheeney Gary S.Director · President and CEO
|
SaleClass A Common Stock | 18,416 | $3.65 | $67,218.40 |
DisclosureSEC source: 0001062993-24-020285 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,400,778 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported above. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.6132 to $3.6858, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| December 05, 2024 Filed Dec 10, 2024 01:05 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,067,245 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-24-020285 · form4.xml · derivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,067,245 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 05, 2024 Filed Dec 10, 2024 01:05 UTC |
Gillheeney Gary S.Director · President and CEO
|
Exercise / conversionClass A Common Stock | 1,067,245 | $0.99 | $1,056,572.55 |
DisclosureSEC source: 0001062993-24-020285 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,419,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 16:48 UTC |
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
ERANI ALBERT10% owner
|
Disposition to issuerClass A Common Stock | 500,000 | $4.06 | $2,028,500.00 |
DisclosureSEC source: 0001062993-24-019880 · form4.xml · nonDerivative · entry 1 GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner ERANI ALBERT · CIK 0001074084 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,403 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 26, 2024. F2 · balance_after: Reflects the total number of securities held by the Group. Only the GN 2016 Family Trust u/a/d August 12, 2016 has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected in the first line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares, except for Glenn H. Nussdorf, who disclaims ownership of the shares held by the GN 2016 Family Trust u/a/d August 12, 2016, except to the extent of his pecuniary interest therein. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:49 UTC |
Wisdom Starr10% owner
Erani Dennis10% owner
|
Disposition to issuerClass A Common Stock | 500,000 | $4.06 | $2,028,500.00 |
DisclosureSEC source: 0001062993-24-019881 · form4.xml · nonDerivative · entry 1 GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,085,403 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 26, 2024. F2 · balance_after: Reflects the total number of securities held by the Group. Only the GN 2016 Family Trust u/a/d August 12, 2016 has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected in the first line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares, except for Glenn H. Nussdorf, who disclaims ownership of the shares held by the GN 2016 Family Trust u/a/d August 12, 2016, except to the extent of his pecuniary interest therein. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Wisdom Starr10% owner
Erani Dennis10% owner
|
Disposition to issuerClass A Common Stock | 2,550,822 | $3.16 | $8,059,832.27 |
DisclosureSEC source: 0001062993-24-019189 · form4.xml · nonDerivative · entry 5 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,585,403 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F6 · balance_after: Reflects the total number of securities held by the Group. Only Glenn H. Nussdorf has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected on the fifth line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Wisdom Starr10% owner
Erani Dennis10% owner
|
Disposition to issuerClass A Common Stock | 3,761,909 | $3.16 | $11,886,503.87 |
DisclosureSEC source: 0001062993-24-019189 · form4.xml · nonDerivative · entry 4 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,136,225 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F5 · balance_after: Reflects the total number of securities held by the Group. Only the Alan Ades 2014 GRAT has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected in the fourth line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares, except for Alan A. Ades, who is the Trustee of the Alan Ades 2014 GRAT, and who disclaims ownership of the shares held by the Alan Ades 2014 GRAT, except to the extent of his pecuniary interest therein. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Wisdom Starr10% owner
Erani Dennis10% owner
|
Disposition to issuerClass A Common Stock | 294,000 | $3.16 | $928,951.80 |
DisclosureSEC source: 0001062993-24-019189 · form4.xml · nonDerivative · entry 3 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,898,134 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F4 · balance_after: Reflects the total number of securities held by the Group. Only Alan A. Ades has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected on the third line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Wisdom Starr10% owner
Erani Dennis10% owner
|
OtherClass A Common Stock | 590,332 | $3.16 | $1,865,272.02 |
DisclosureSEC source: 0001062993-24-019189 · form4.xml · nonDerivative · entry 2 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,192,134 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F3 · balance_after: Reflects the total number of securities held by the Group. Only RED Holdings, LLC has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected in the second line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares, except for Albert Erani, who is the sole manager of RED Holdings, LLC, and who disclaims ownership of the shares held by RED Holdings, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Wisdom Starr10% owner
Erani Dennis10% owner
|
OtherClass A Common Stock | 224,668 | $3.16 | $709,883.48 |
DisclosureSEC source: 0001062993-24-019189 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Wisdom Starr · CIK 0001760694 · 10% owner GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 · CIK 0001757452 · 10% owner Erani Dennis · CIK 0001760685 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,782,466 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F2 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected on the first line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
|
Disposition to issuerClass A Common Stock | 2,550,822 | $3.16 | $8,059,832.27 |
DisclosureSEC source: 0001062993-24-019188 · form4.xml · nonDerivative · entry 5 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,585,403 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F6 · balance_after: Reflects the total number of securities held by the Group. Only Glenn H. Nussdorf has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected on the fifth line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
|
Disposition to issuerClass A Common Stock | 3,761,909 | $3.16 | $11,886,503.87 |
DisclosureSEC source: 0001062993-24-019188 · form4.xml · nonDerivative · entry 4 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,136,225 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F5 · balance_after: Reflects the total number of securities held by the Group. Only the Alan Ades 2014 GRAT has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected in the fourth line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares, except for Alan A. Ades, who is the Trustee of the Alan Ades 2014 GRAT, and who disclaims ownership of the shares held by the Alan Ades 2014 GRAT, except to the extent of his pecuniary interest therein. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
|
Disposition to issuerClass A Common Stock | 294,000 | $3.16 | $928,951.80 |
DisclosureSEC source: 0001062993-24-019188 · form4.xml · nonDerivative · entry 3 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,898,134 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F4 · balance_after: Reflects the total number of securities held by the Group. Only Alan A. Ades has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected on the third line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
|
OtherClass A Common Stock | 590,332 | $3.16 | $1,865,272.02 |
DisclosureSEC source: 0001062993-24-019188 · form4.xml · nonDerivative · entry 2 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,192,134 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F3 · balance_after: Reflects the total number of securities held by the Group. Only RED Holdings, LLC has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected in the second line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares, except for Albert Erani, who is the sole manager of RED Holdings, LLC, and who disclaims ownership of the shares held by RED Holdings, LLC, except to the extent of his pecuniary interest therein. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 19:27 UTC |
ERANI ALBERT10% owner
RED Holdings, LLC10% owner
Ades Alan A.Director · 10% owner
Alan Ades 2014 GRAT10% owner
NUSSDORF GLENN HDirector · 10% owner
Organo PFG LLC10% owner
Organo Investors LLC10% owner
|
OtherClass A Common Stock | 224,668 | $3.16 | $709,883.48 |
DisclosureSEC source: 0001062993-24-019188 · form4.xml · nonDerivative · entry 1 ERANI ALBERT · CIK 0001074084 · 10% owner RED Holdings, LLC · CIK 0001900525 · 10% owner Ades Alan A. · CIK 0001757286 · Director · 10% owner Alan Ades 2014 GRAT · CIK 0001757567 · 10% owner NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner Dennis Erani 2012 Issue Trust dated 12/20/12 · CIK 0001757455 · 10% owner Organo PFG LLC · CIK 0001757580 · 10% owner Organo Investors LLC · CIK 0001757573 · 10% owner GN 2016 Family Trust u/a/d August 12, 2016 · CIK 0001757453 · 10% owner Albert Erani Family Trust dated 12/29/2012 · CIK 0001760663 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,782,466 F1 · price: The price reported in Column 4 is the 10-day trailing volume weighted average price of the Class A common stock as of market close on November 11, 2024. F2 · balance_after: Reflects the total number of securities held by the Group. Only Albert Erani has a pecuniary interest in the shares redeemed by Organogenesis pursuant to a Stock Repurchase Agreement reflected on the first line of Table I of this Form 4. None of the other members of the Group has a pecuniary interest in such shares. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 17:03 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 317 | $3.09 | $979.53 |
DisclosureSEC source: 0001062993-24-013923 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,766 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:22 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 1,752 | $2.80 | $4,905.60 |
DisclosureSEC source: 0001062993-24-007932 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,268 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:23 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 1,974 | $2.80 | $5,527.20 |
DisclosureSEC source: 0001062993-24-007935 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,272 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:23 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 2,497 | $2.80 | $6,991.60 |
DisclosureSEC source: 0001062993-24-007937 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 809,082 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:23 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 1,977 | $2.80 | $5,535.60 |
DisclosureSEC source: 0001062993-24-007934 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,809 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:22 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 10,113 | $2.80 | $28,316.40 |
DisclosureSEC source: 0001062993-24-007931 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,351,949 Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 20:19 UTC |
Bilbo PatrickChief Operating Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 152,250 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001062993-24-007462 · form4.xml · derivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 152,250 shares Expires 2024-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 20:19 UTC |
Bilbo PatrickChief Operating Officer
|
Exercise / conversionClass A Common Stock | 152,250 | $1.18 | $179,655.00 |
DisclosureSEC source: 0001062993-24-007462 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 811,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:21 UTC |
Driscoll Michael JosephDirector
|
GrantClass A Common Stock | 51,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004307 · form4.xml · nonDerivative · entry 1 Driscoll Michael Joseph · CIK 0001912097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,304 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2025. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:24 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantStock Option (Right to Buy) · Derivative | 79,068 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004315 · form4.xml · derivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,068 Underlying: Class A Common Stock · 79,068 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:24 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
GrantClass A Common Stock | 43,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004315 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,020 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:20 UTC |
Leibowitz Arthur SDirector
|
GrantClass A Common Stock | 51,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004306 · form4.xml · nonDerivative · entry 1 Leibowitz Arthur S · CIK 0001467329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,611 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2025. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:23 UTC |
Freedman LoriChief Admin. and Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 276,737 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004312 · form4.xml · derivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,737 Underlying: Class A Common Stock · 276,737 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:23 UTC |
Freedman LoriChief Admin. and Legal Officer
|
GrantClass A Common Stock | 153,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004312 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,246 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:20 UTC |
Giacomin Jon LDirector
|
GrantClass A Common Stock | 51,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004305 · form4.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,623 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2025. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:24 UTC |
Francisco DavidChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 289,915 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004314 · form4.xml · derivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,915 Underlying: Class A Common Stock · 289,915 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:24 UTC |
Francisco DavidChief Financial Officer
|
GrantClass A Common Stock | 160,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004314 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,996 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC |
Grow BrianChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 313,636 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004313 · form4.xml · derivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,636 Underlying: Class A Common Stock · 313,636 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC |
Grow BrianChief Commercial Officer
|
GrantClass A Common Stock | 173,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004313 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 522,786 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC |
Gillheeney Gary S.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 1,238,729 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004310 · form4.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,238,729 Underlying: Class A Common Stock · 1,238,729 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.